HCV prevalence in methadone maintenance: Self-report versus serum test

American Journal of Health Behavior

Volumn 29, Issue 5, 2005, Pages 387-394

  Weaver, Michael F ^a,b   Cropsey, Karen L ^b   Fox, Stephanie A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Hepatitis C virus; Injection drug use; Methadone maintenance

Indexed keywords

EID: 25844449187     PISSN: 10873244     EISSN: None     Source Type: Journal    
DOI: 10.5993/AJHB.29.5.1     Document Type: Review

References (23)

1. Centers for Disease Control and Prevention. National hepatitis C prevention strategy: a comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Centers for Disease Control and Prevention, 2001; p. 4. Available at http://www.cdc.gov/ncidod/diseases/ hepatitis/c/plan/strategy.pdf. Accessed on September 21, 2004.
2. Alter MJ, Kruszon-Moran MD, Nainan OV, et al. The prevalence of hepatitis C virus infections in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
3. Thorpe LE, Ouellet LJ, Hershow R. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645-653.
4. Hagan H, Thiede H, Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
5. Kaldor JM, Archer GT, Buring ML, et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust. 1992;157:227-230.
6. D'Souza G, Arafat R, Hwang L, et al. Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services' sexually transmitted disease clinics. J Viral Hepat. 2003;10:134-140.
7. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36(Suppl):S99-S105.
8. Pawlotsky J-M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96-102.
9. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
10. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253-263.
11. Schlicting EG, Johnson ME, Brems C. Validity of injecting drug users' self report of hepatitis A, B, and C. Clinical Laboratory Science. 2003;16:99-106.
12. Stein MD, Maksad J, Clarke J. Hepatits C disease among injection drug users: knowledge, perceived risks, and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211-215.
13. National Institutes of Health-Centers for Disease Control and Prevention (NIH-CDC). Effective Medical Treatment Of Heroin Addiction. NIH Consensus Statement, 1997;15(6):1-38.
14. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A current perspective. The Western Journal of Medicine. 1990;152:588-599.
15. rd Ed. American Society of Addiction Medicine, Chevy Chase, MD, 2003:751-766.
16. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis. 2001;20:19-31.
17. Best D, Noble A, Finch E. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br Med J. 1999;319:290-291.
18. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in an addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703-707.
19. Astone J, Strauss SM, Vassilev ZP, et al. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ. 2003;33:107-117.
20. Strauss SM, Astone J, Vassilev ZP, et al. Gaps in the drug-free and methadone treatment program response to hepatitis C. J Subst Abuse Treat. 2003;24:291-297.
21. Seeff LB. The natural history of viral hepatitis, type C. Semin Gastrointest Dis. 1995;6:20-27.
22. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV positive injection drug users. Addiction. 1998;93:1191-1197.
23. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993;88:517-526.